|Title||The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug.|
|Publication Type||Journal Article|
|Year of Publication||1995|
|Authors||Savarese JJ, Lien CA, Belmont MR, Rubin L|
|Journal||Acta Anaesthesiol Scand Suppl|
|Keywords||Cholinesterases, Drug Design, Drug Industry, Half-Life, Hospitals, General, Humans, Hydrolysis, Isoquinolines, Neuromuscular Nondepolarizing Agents, Succinylcholine|
Mivacurium is a benzylisoquinolinium diester. The drug is a nondepolarizing relaxant which is hydrolysed by plasma cholinesterase at 70-88% of the rate of suxamethonium. Enzymatic hydrolysis gives the drug its short duration of action. The length of paralysis is about 2-2.5 times that of suxamethonium and one-half to one-third that of the intermediate-acting nondepolarizers. The development of mivacurium represents a collaboration between industrial pharmacologists and chemists at Burroughs Wellcome Co. (USA) and investigators at the Massachusetts General Hospital, Boston, MA, USA.
|Alternate Journal||Acta Anaesthesiol Scand Suppl|